Loading
A phase 2 trial of Intismeran autogene, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) is a phase 2 interventional study registered as NCT07221474 by Merck Sharp & Dohme LLC, with 180 participants planned, started 2025-12-12 and due to reach its primary completion in 2029-07-02. Interventions recorded: Intismeran Autogene, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel. Conditions listed: Squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Small-cell lung cancer.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Carboplatin.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Small-cell lung cancer.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD), Pembrolizumab.
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Merck & Co. (MSD).
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Pembrolizumab, Immune checkpoint inhibitors.